Introduction
============

Essential hypertension is a common disease in the field of cardiology in clinical practice at present, and causal factors include mainly genetic, dietary and mental factors ([@b1-etm-0-0-5544]--[@b3-etm-0-0-5544]). The main risk for essential hypertension is the persistent elevation in blood pressure, thus increasing the left ventricular burden in patients ([@b4-etm-0-0-5544]--[@b6-etm-0-0-5544]). Recent research indicates that, with the development of the disease, cardiac structure and function in patients change significantly; in particular, the change is more obvious in hypertensive patients with coronary artery disease, and the fatality rate is clinically higher ([@b7-etm-0-0-5544]--[@b9-etm-0-0-5544]). For these patients, percutaneous coronary intervention (PCI) is the most clinically effective therapy, which can effectively restore myocardial perfusion, ameliorate systolic synchrony and cardiac function ([@b10-etm-0-0-5544]). When using PCI it is important to evaluate ventricular structure and function in hypertensive patients with coronary artery disease accurately and in real-time, to assist doctors to accurately assess the degree of illness, evaluate the effect of surgery, adjust medication regimens and assess patient prognosis.

Echocardiography is a non-invasive method for the diagnosis and follow-up of patients with hypertension with coronary heart disease, and the emergence of multiple new technologies makes echocardiography more widely applied ([@b11-etm-0-0-5544],[@b12-etm-0-0-5544]). Real-time three-dimensional echocardiography (RT-3DU) is the latest technology used clinically. It is based on two-dimensional ultrasound technology, and it binds with the most advanced scanning technology to increase the effect of the z-axis direction and combines with the calculation and statistics of parameters and comparative analysis via three-dimensional parameter database to obtain accurate three-dimensional echocardiography, thus displaying cardiac conditions in patients in real-time ([@b13-etm-0-0-5544],[@b14-etm-0-0-5544]). Additionally, real-time three-dimensional echocardiography can more accurately and directly evaluate changes in ventricular structure and heart function of patients, including heart volume, myocardial contraction, heart function and other important parameters, thus reducing the reliance on other auxiliary means ([@b15-etm-0-0-5544]). RT-3DU has the advantages of rapid imaging and easy operation, which can multi-directionally display three-dimensional structure of plaque, spatial relationship and activity under the impact of blood flow, thus providing more information for clinical diagnosis ([@b16-etm-0-0-5544]). This study aimed to evaluate changes in left ventricular structure and function in hypertensive patients with coronary artery disease after PCI by real-time three-dimensional echocardiography, which has great research value in improving the quality of clinical PCI surgery, and to provide a theoretical basis for the wide development and application of real-time three-dimensional echocardiography.

Patients and methods
====================

### General data

Two hundred and eighty hypertensive patients with coronary artery disease undergoing PCI in our hospital from May 2014 to May 2017 were enrolled and screened in the present study, while 120 cases with the same illness that did not receive PCI were enrolled as the control group. Patients were assessed by real-time three-dimensional echocardiography at preoperative day 2, postoperative 3 months and 9 months in our study.

### Inclusion criteria

Hypertensive patients with coronary artery disease, aged 50--80 years, with body mass index (BMI) within 19--25 kg/m^2^, were included.

### Exclusion criteria

The following patients were excluded: i) patients with A, B, C, D or E hepatitis virus; ii) patients with human immunodeficiency virus infection; iii) patients with other malignant tumors; iv) patients with autoimmune diseases; v) patients with cardiac structure abnormalities; vi) patients with a variety of mental disorders; vii) patients with renal insufficiency; viii) patients with hepatic insufficiency; ix) patients with other heart diseases; x) patients with other cardiac insufficiencies.

### Causes for patient loss and countermeasures

The reasons for patient loss included: i) patients withdrew from this series of tests; ii) patients transferred to other hospitals for treatment during the testing; iii) patients no longer met the test conditions due to their physical condition. Therefore, the remaining subjects were supplemented into the corresponding test group in a proportion of 1:1.

### Ethical considerations

Patients and lineal relatives signed an inform consent form to participate in this clinical study after fully understanding the research process. The related diagnosis, treatment and monitoring measures for patients were in accordance with the related principles of clinical guidelines, so as to fully guarantee the medical treatment and safety of the patients. The information and medical records of patients enrolled in this study were kept anonymous to protect the privacy of patients. The test program was registered in the Chinese Clinical Trial Registry, and Ottawa Group Statement for Clinical Trial Registration was followed in this test.

### Strict double-blind principle

The researchers were divided into four groups: The first group of researchers was responsible for screening the test subjects that were randomly divided into two groups. The second group of researchers was responsible for the surgery in the PCI group. The third group of researchers was responsible for recording real-time three-dimensional echocardiography at different time points and collecting other related data. The fourth group of researchers was responsible for collecting data, statistics and analysis, and preparation of the manuscript. The grouping of the test subjects was kept strictly anonymous. The test subjects and researchers who were responsible for clinical analysis and data collection did not know the specific grouping of the test subjects, so as to ensure that the detection and data were without human interference. Researchers in the four study groups remained anonymous for each operation.

### Baseline conditions of subjects

The age, smoking history, family history, serum creatinine, homocysteine, high-sensitivity C-reactive protein (hs-CRP), blood glucose, clinical medication and other baseline data of the enrolled patients are shown in [Table I](#tI-etm-0-0-5544){ref-type="table"}.

### Image collection of real-time three-dimensional echocardiography

Patients were assessed by real-time three-dimensional echocardiography using color Doppler ultrasonic diagnostic apparatus (iE33; Philips Healthcare, Andover, MA, USA). The changes in echocardiography were recorded synchronously during the determination. Patients were guided to take the left lateral position with quiet breathing. The three-dimensional probe of the apparatus was placed at the apex of the patient, and the probe angle was adjusted according to the feedback information of the image to obtain the best real-time three-dimensional image. Four cardiac cycles of real-time three-dimensional images were recorded, and the image parameters and related data were transferred to a workstation for offline analysis ([Fig. 1](#f1-etm-0-0-5544){ref-type="fig"}).

### Image processing and analysis

After working offline, QLAB8.1 quantitative analysis software in the workstation was opened. According to the ventricular conditions of patients, the appropriate analysis plug-in was selected to obtain the optimum results of the quantitative analysis. The important parameters of the left ventricle were mainly analyzed, including left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF); the maximum difference and standard deviation of time from six middle segments of the myocardium and six basal ones to the minimum systolic volume were recorded as Tmsv-12Dif and Tmsv-12SD; the maximum difference and standard deviation of time from sixteen segments of the myocardium to the minimal systolic volume were recorded as Tmsv-16Dif and Tmsv-16SD; the maximum difference and standard deviation of time from segment of the myocardium to the minimal systolic volume (Tmsv) and its systolic time were recorded as Tmsv-Dif and Tmsv-SD; the maximum difference and standard deviation of time from six basal segments of the myocardium to the minimal systolic volume were recorded as Tmsv-6Dif and Tmsv-6SD; left ventricular end-diastolic volume (LVEDV) and the left ventricular volume-time curves (VTC).

### Clinical biochemical parameters

In addition to real-time three-dimensional echocardiography data, systolic blood pressure (mmHg), diastolic blood pressure (mmHg), hemoglobin (g/dl), hematocrit (%) and other clinical biochemical parameters in patients were detected.

### Statistical analysis

SPSS 20.0 software (SPSS, Inc., Armonk, NY, USA) was used to statistically analyze the data for detection and observation. The Chi-square test was adopted for enumeration data, and analysis of variance (ANOVA) was utilized for measurement data, which are expressed as mean ± standard deviation. P\<0.05 or P\<0.01 were indicative of statistically significant differences.

Results
=======

### Changes in left ventricular volume, ejection and systolic function at different time points in the hypertensive patients with coronary artery disease receiving PCI

Changes in left ventricular volume, ejection and systolic function in patients receiving PCI were assessed. Before PCI, there were no significant differences in LVEDV, LVESV and LVEF between the PCI and control group (P\>0.05). However, results at 3 and 9 months after PCI indicated that the LVESV level in patients of the PCI group was significantly reduced when compared with that of the control group (P\<0.05). Additionally, the LVEF value in patients of the PCI group was significantly increased when compared with that of the control group (P\<0.05) ([Table II](#tII-etm-0-0-5544){ref-type="table"}).

### Changes in left ventricular systolic volume and systolic time at different time points in hypertensive patients with coronary artery disease receiving PCI

Changes in left ventricular systolic volume and systolic time in patients receiving PCI were assessed. Before PCI, there were no significant differences in the maximum difference and standard deviation of time from segment of the myocardium to the minimal systolic volume and other important parameters between the PCI and control group (P\>0.05). However, results at 3 and 9 months after PCI indicated that the maximum difference and standard deviation of time from segment of the myocardium to the minimal systolic volume and other important parameter levels were significantly reduced when compared with those of the control group (P\<0.05) ([Table III](#tIII-etm-0-0-5544){ref-type="table"}).

### Comparisons of other functional parameter levels of the left ventricular in subjects

Comparisons of other function parameter levels of the left ventricular in subjects were carried out. Compared with that in the control group, global longitudinal strain (GLS) (%) level in patients of the PCI group was significantly increased (P\<0.05). Additionally, global longitudinal systolic strain rates (GLSRs) (1/sec) and ejection fraction (EF) (%) level in patients of the PCI group were significantly reduced (P\<0.05) ([Table IV](#tIV-etm-0-0-5544){ref-type="table"}).

### Comparisons of routine heart structure parameters of the left ventricular in subjects

Comparisons of routine heart structure parameters of left ventricular in subjects were carried out. Compared with that in the control group, the left ventricular mass index (LVMI) (g/m^2^) level in patients of the PCI group was significantly increased (P\<0.05). Additionally, left ventricular end-diastolic dimension (LVEDD) (cm), interventricular septum thickness at end-diastole (IVSD) (cm) and left ventricular posterior wall depth (LVPWD) (cm) levels in patients of the PCI group were significantly reduced (P\<0.05) ([Table V](#tV-etm-0-0-5544){ref-type="table"}).

### Comparisons of clinical biochemical parameters in subjects

Comparisons of clinical biochemical parameters in subjects: Compared with those in the control group, systolic blood pressure (mmHg) and hemoglobin (g/dl) level in patients of the PCI group were significantly increased (P\<0.05). Additionally, diastolic blood pressure (mmHg) and hematocrit (%) level in the patients of the PCI group had no distinct changes (P\>0.05) ([Table VI](#tVI-etm-0-0-5544){ref-type="table"}).

Discussion
==========

Essential hypertension is a common disease in the field of cardiology in clinical practice at present, and its cause is not clear, but mainly includes genetic, dietary and mental factors. The main risk for essential hypertension is the persistent elevation in blood pressure, thus increasing the left ventricular burden in patients, finally incurring coronary heart disease. The routine left ventricular systolic function is measured by M-ultrasound or two-dimensional echocardiography Simpson\'s method with the premise of regular morphology of heart ([@b17-etm-0-0-5544]--[@b19-etm-0-0-5544]). However, in pathological conditions, such as ventricular aneurysm, ventricular wall motion abnormality and other cardiac morphological or functional abnormalities, its accuracy is significantly affected. Real-time three-dimensional echocardiography has a three-dimensional matrix probe controlled by a computer, and works by a mechanism of fast scanning via multi-directional sound beam to emit three-dimensional scanning sound beam. Due to the simultaneous scanning of sound beam in three directions perpendicular to each other, a three-dimensional structural image database is formed that covers various regions of the heart with the shape of a pyramid, thus obtaining real-time three-dimensional image of the heart. In contrast, three-dimensional echocardiography can automatically analyze and obtain left ventricular volume on the basis of direct tracking of the endocardium, which overcomes the defects of geometric assumption, and the measured value is more close to the actual value ([@b5-etm-0-0-5544]). Previous studies have shown that three-dimensional echocardiography used to measure left ventricular end-diastolic volume is closer to magnetic resonance imaging (MRI) which is the gold standard to evaluate left ventricular volume, indicating that three-dimensional echocardiography is more accurate than the traditional two-dimensional echocardiography ([@b20-etm-0-0-5544]--[@b25-etm-0-0-5544]).

Three-dimensional echocardiography can also provide quantitative indices of synchronous contractions in each segment of the left ventricle. The three key time points, 2 days before surgery, 3 and 9 months after surgery, were selected in this study, revealing that at 3 months after PCI, the kinetic energy of the left ventricle in patients was significantly increased. At 9 months after surgery, left ventricular function in patients basically returned to normal, which was consistent with the results of previous studies. In this study, LVEDV in hypertensive patients with coronary artery disease after PCI was reduced when compared to that before surgery, while LVESV was decreased, and LVEF was increased. Meanwhile, it was found that at day 2 before PCI, there were no significant differences in the maximum difference and standard deviation of time from segment of the myocardium to the minimal systolic volume and other important parameters between the PCI and control group. Additionally, the results at 3 and 9 months after surgery indicated that the maximum difference and standard deviation of time from segment of the myocardium to the minimal systolic volume and other important parameter levels were obviously reduced in patients in the PCI group, revealing that postoperative left ventricular function gradually returned to the normal level. Compared with the control group, the GLS (%) level in patients of the PCI group was significantly increased, while GLSRs (1/sec) and EF (%) level in patients of the PCI group were significantly reduced (P\<0.05). GLS represents the extent of the shortening of the left ventricle along the longitudinal fibrous direction of the myocardium during the systolic period. Due to the long-term effect of blood flow, fibrosis occurs, indicating that postoperative left ventricular function in patients returned to normal. Additionally, the LVMI (g/m^2^) level in patients of the PCI group was significantly increased (P\<0.05), while LVEDD (cm), IVSD (cm) and LVPWD (cm) levels in patients of the PCI group were significantly reduced (P\<0.05). Therein, triglyceride is an important factor to affect the level of LVMI, representing the extent of left ventricular hypertrophy. Finally, systolic blood pressure (mmHg) and hemoglobin (g/dl) level in the patients of the PCI group were significantly increased (P\<0.05). Additionally, diastolic blood pressure (mmHg) and hematocrit (%) level in patients of the PCI group had no distinct changes (P\>0.05). The above results indicated that left ventricular systolic synchrony and global systolic function were gradually improved after PCI.

In summary, real-time three-dimensional echocardiography can accurately and efficiently evaluate the changes in left ventricular structure and function in hypertensive patients with coronary artery disease receiving PCI, which can replace the traditional two-dimensional ultrasound. In order to further enhance the success rate of PCI and detect heart function and structural changes in patients, real-time three-dimensional echocardiography is worthy of clinical popularization and application as an effective detection means.

![Real-time three-dimensional echocardiography and two-dimensional echocardiography. Left, real-time three-dimensional echocardiography; right, two-dimensional echocardiography.](etm-15-02-1493-g00){#f1-etm-0-0-5544}

###### 

Comparisons of general data of the hypertensive patients.

  Parameters                       PCI group     Control group   P-value
  -------------------------------- ------------- --------------- ---------
  Mean age (years)                 62.47±3.82    64.04±4.19      0.842
  Male, n (%)                      193 (68.9)      84 (70.0)     0.747
  Smoking, n (%)                   104 (37.1)      40 (33.3)     0.673
  Fasting blood-glucose (mmol/l)   5.43±0.43     5.51±0.35       0.913
  Diabetes, n (%)                  79 (28.2)       32 (26.7)     0.583
  Serum creatinine (µmol/l)        92.1±9.1        93.1±11.8     0.738
  Homocysteine (µmol/l)            13.8±2.4      13.9±1.7        0.545
  hs-CRP (mg/l)                      0.89±0.17     0.91±0.21     0.701
  Aspirin, n (%)                   280 (100.0)     120 (100.0)   0.662
  Clopidogrel, n (%)               242 (86.4)    105 (87.5)      0.843
  Ticagrelor, n (%)                  38 (13.6)     15 (12.5)     0.274
  Statins, n (%)                   276 (98.6)    114 (95.0)      0.837
  ACEI/ARB, n (%)                  185 (66.1)      81 (67.5)     0.583
  β-blocker, n (%)                 219 (78.2)      93 (77.5)     0.669
  Calcium antagonist, n (%)          86 (30.7)     38 (31.7)     0.343
  Nitrates, n (%)                  251 (89.6)    109 (90.8)      0.554

ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor antagonist.

###### 

Changes in left ventricular volume, ejection and systolic function at different time points in patients receiving PCI.

  Parameters   Test time                  Control group (n=120)   PCI group (n=280)   P-value
  ------------ -------------------------- ----------------------- ------------------- ---------
  LVEDV (ml)   2 days before treatment    92.41±8.74              92.08±7.09          0.311
               3 months after treatment   92.05±8.32              92.54±5.91          0.284
               9 months after treatment   92.05±6.71              92.07±8.22          0.536
  LVESV (ml)   2 days before treatment    49.28±4.92              48.93±5.01          0.723
               3 months after treatment   53.06±7.04              47.83±6.61          0.015
               9 months after treatment   49.33±4.29              44.11±9.72          0.013
  LVEF (%)     2 days before treatment    46.05±3.21              46.04±3.92          0.542
               3 months after treatment   45.94±3.19              49.25±3.86          0.006
               9 months after treatment   46.38±4.33              51.74±3.22          0.011

###### 

Changes in left ventricular systolic volume and systolic function at different time points in hypertensive patients with coronary artery disease receiving PCI.

  Parameters   Test time                  Control group (n=120)   PCI group (n=280)   P-value
  ------------ -------------------------- ----------------------- ------------------- ---------
  Tmsv-16SD    2 days before treatment    49.25±14.28             40.19±11.93         0.662
  Tmsv-12SD                               43.66±5.91              44.33±7.06          0.187
  Tmsv-6SD                                43.27±8.45              43.18±7.32          0.243
  Tmsv-16Dif                              79.15±11.31             80.18±12.07         0.228
  Tmsv-12Dif                              70.43±10.03             69.18±9.06          0.184
  Tmsv-6 Dif                              59.45±8.25              59.02±9.51          0.394
  Tmsv-16SD    3 months after treatment   53.73±11.02             46.06±9.83          0.011
  Tmsv-12SD                               39.21±4.22              21.36±3.11          0.021
  Tmsv-6SD                                39.42±2.19              19.04±2.33          0.033
  Tmsv-16Dif                              80.16±9.42              49.33±15.15         0.018
  Tmsv-12Dif                              70.62±7.14              50.16±2.94          0.019
  Tmsv-6 Dif                              63.42±7.01              51.22±4.05          0.003
  Tmsv-16SD    9 months after treatment   49.99±3.84              19.55±3.21          0.014
  Tmsv-12SD                               39.88±3.52              20.71±3.83          0.031
  Tmsv-6SD                                39.07±5.83              20.21±3.14          0.008
  Tmsv-16Dif                              69.21±4.05              51.22±5.05          0.015
  Tmsv-12Dif                              59.03±11.52             41.37±8.21          0.018
  Tmsv-6 Dif                              60.41±9.04              41.62±5.64          0.009

###### 

Comparisons of other function parameters of left ventricular in subjects (mean ± SD).

  Group           No. of cases   GLS (%)                                                     GLSRs (1/sec)                                             EF (%)
  --------------- -------------- ----------------------------------------------------------- --------------------------------------------------------- ------------
  PCI group       280            −19.06±1.37^[a](#tfn2-etm-0-0-5544){ref-type="table-fn"}^   1.05±0.29^[a](#tfn2-etm-0-0-5544){ref-type="table-fn"}^   65.33±6.25
  Control group   120            −22.33±2.15                                                 1.25±0.31                                                 67.03±5.75

P\<0.05, compared with the control group.

###### 

Comparisons routine heart structure parameters of left ventricular in subjects (mean ± SD).

  Group           No. of cases   LVEDD (cm)                                                IVSD (cm)                                                 LVPWD (cm)                                                LVMI (g/m^2^)
  --------------- -------------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------
  PCI group       280            4.86±0.37^[a](#tfn3-etm-0-0-5544){ref-type="table-fn"}^   1.04±0.29^[a](#tfn3-etm-0-0-5544){ref-type="table-fn"}^   0.94±0.26^[a](#tfn3-etm-0-0-5544){ref-type="table-fn"}^   65.33±6.25^[a](#tfn3-etm-0-0-5544){ref-type="table-fn"}^
  Control group   120            4.33±0.15                                                 0.88±0.31                                                 0.78±0.33                                                 67.03±5.75

P\<0.05, compared with the control group.

###### 

Comparisons of clinical biochemical parameters in subjects (mean ± SD).

  Group           No. of cases   Systolic blood pressure (mmHg)                             Diastolic blood pressure (mmHg)   Hemoglobin (g/dl)                                         Hematocrit (%)
  --------------- -------------- ---------------------------------------------------------- --------------------------------- --------------------------------------------------------- ----------------
  PCI group       280            133.6±10.7^[a](#tfn4-etm-0-0-5544){ref-type="table-fn"}^   76.4±9.2                          11.94±2.6^[a](#tfn4-etm-0-0-5544){ref-type="table-fn"}^   35.8±4.5
  Control group   120            124.3±9.5                                                  75.8±9.3                          10.78±3.1                                                 36.3±5.7

P\<0.05, compared with the control group.
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